Envista just downgraded at Goldman Sachs, here’s why

Goldman Sachs downgraded Envista to Sell from Buy with a $22 price target. The firm’s downgrade reflects the view that Envista’s product positioning and limited innovation pipeline in implants and equipment will make it more challenging to accelerate topline growth to its target and expand margins. Goldman also expects continued pressure in equipment given increased competition from foreign brands and softer sales following the equipment rebranding to Dexis, the analyst added.